Ratio Therapeutics has granted Macrocyclics exclusive manufacturing and distribution rights to Ratio’s bifunctional chelator, Macropa.
Macropa, a chelator for actinium-225 (Ac-225), labels quickly at room temperature, providing an advantage when working with proteins or vectors that degrade when heated, according to Boston-based Ratio.
Texas-based Macrocyclics, a subsidiary of Orano Med, is a contract development and manufacturing organization specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The agreement will enable access to Macropa in Japan, Canada, Australia, and a majority of Europe, according to Ratio.
